The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab

Seminars in Arthritis and Rheumatism

Volumn 47, Issue 6, 2018, Pages 757-764

  Diaz Torne, Cesar ^a   Ortiz, Maria dels Angels ^a   Moya, Patricia ^a   Hernandez, Maria Victoria ^b   Reina, Delia ^c   Castellvi, Ivan ^a   De Agustin, Juan Jose ^d   Fuente, Diana de la ^e   Corominas, Hector ^c   Sanmarti, Raimon ^b   Zamora, Carlos ^a   Cantó, Elisabet ^a   Vidal, Silvia ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Servicio de Medicina Intensiva   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL DE VILADECANS   (Spain)

Author keywords

IL 6; Rheumatoid arthritis; sIL 6R; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DAS28; DISEASE DURATION; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; EUROPEAN LEAGUE AGAINST RHEUMATISM RESPONSE CRITERIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MUSCULOSKELETAL DISEASE ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; TREATMENT DURATION; BLOOD; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6;

EID: 85034055565     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2017.10.022     Document Type: Article

References (35)

1. Wang, F., Sengupta, T.K., Zhong, Z., Ivashkiv, L.B., Regulation of the balance of cytokine production and the signal transducer and activator of transcription (STAT) transcription factor activity by cytokines and inflammatory synovial fluids. J Exp Med 182 (1995), 1825–1831.
2. Kimura, A., Kishimoto, T., IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40 (2010), 1830–1835.
3. Hunter, C.A., Jones, S.A., IL-6 as a keystone cytokine in health and disease. Nat Immunol 16 (2015), 448–457.
4. Wolf, J., Rose-John, S., Garbers, C., Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 70 (2014), 11–20.
5. Rose-John, S., Scheller, J., Elson, G., Jones, S.A., Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80 (2006), 227–236.
6. Rose-John, S., IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8 (2012), 1237–1247.
7. Gabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381 (2013), 1541–1550.
8. Genovese, M.C., McKay, J.D., Nasonov, E.L., Mysler, E.F., da Silva, N.A., Alecock, E., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58 (2008), 2968–2980.
9. Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., et al. The American Rheumatism Association1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988), 315–324.
10. Sanmarti, R., Garcia-Rodriguez, S., Alvaro-Gracia, J.M., Andreu, J.L., Balsa, A., Caliz, R., et al. 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. Reumatol Clin 11 (2015), 279–294.
11. Smolen, J.S., Landewe, R., Breedveld, F.C., Buch, M., Burmester, G., Dougados, M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73 (2014), 492–509.
12. van Gestel, A.M., Prevoo, M.L., van ’t Hof, M.A., van Rijswijk, M.H., van de Putte, L.B., van Riel, P.L., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39 (1996), 34–40.
13. Norusis, M., SPSS 13.s Statistical procedures companion. 2004, Prentice Hall, Inc, New Jersey.
14. Shimamoto, K., Ito, T., Ozaki, Y., Amuro, H., Tanaka, A., Nishizawa, T., et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol 40 (2013), 1074–1081.
15. Nishina, N., Kikuchi, J., Hashizume, M., Yoshimoto, K., Kameda, H., Takeuchi, T., Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. Ann Rheum Dis 73 (2014), 945–947.
16. Lee, S.J., Park, W., Park, S.H., Shim, S.C., Baek, H.J., Yoo, D.H., et al. Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients. J Immunol Res, 2015, 2015, 487230.
17. de Benedetti, F., Massa, M., Robbioni, P., Ravelli, A., Burgio, G.R., Martini, A., Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34 (1991), 1158–1163.
18. Wang, J., Platt, A., Upmanyu, R., Germer, S., Lei, G., Rabe, C., et al. IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open, 3, 2013, e003199.
19. Hashimoto, J., Garnero, P., van der Heijde, D., Miyasaka, N., Yamamoto, K., Kawai, S., et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol 21 (2011), 10–15.
20. Nishimoto, N., Amano, K., Hirabayashi, Y., Horiuchi, T., Ishii, T., Iwahashi, M., et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 24 (2014), 17–25.
21. Peters, M., Jacobs, S., Ehlers, M., Vollmer, P., Mullberg, J., Wolf, E., et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 183 (1996), 1399–1406.
22. Maldonado-Montoro, M., Canadas-Garre, M., Gonzalez-Utrilla, A., Plaza-Plaza, J.C., Calleja-Hernandez, M.A., Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Pharmacol Res 111 (2016), 264–271.
23. Narvaez, J., Magallares, B., Diaz Torne, C., Hernandez, M.V., Reina, D., Corominas, H., et al. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Semin Arthritis Rheum 45 (2016), 386–390.
24. Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., Kakehi, T., Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112 (2008), 3959–3964.
25. De Benedetti, F., Massa, M., Pignatti, P., Albani, S., Novick, D., Martini, A., Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 93 (1994), 2114–2119.
26. Lust, J.A., Donovan, K.A., Kline, M.P., Greipp, P.R., Kyle, R.A., Maihle, N.J., Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 4 (1992), 96–100.
27. Mullberg, J., Schooltink, H., Stoyan, T., Gunther, M., Graeve, L., Buse, G., et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 23 (1993), 473–480.
28. Montero-Julian, F.A., Klein, B., Gautherot, E., Brailly, H., Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 85 (1995), 917–924.
29. Chalaris, A., Rabe, B., Paliga, K., Lange, H., Laskay, T., Fielding, C.A., et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 110 (2007), 1748–1755.
30. Jones, S.A., Horiuchi, S., Topley, N., Yamamoto, N., Fuller, G.M., The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 15 (2001), 43–58.
31. Portier, M., Lees, D., Caron, E., Jourdan, M., Boiron, J.M., Bataille, R., et al. Up-regulation of interleukin (IL)-6 receptor gene expression in vitro and in vivo in IL-6 deprived myeloma cells. FEBS Lett 302 (1992), 35–38.
32. Kojima, T., Yabe, Y., Kaneko, A., Hirano, Y., Ishikawa, H., Hayashi, M., et al. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Mod Rheumatol 23 (2013), 977–985.
33. Kneepkens, E.L., van den Oever, I., Plasencia, C.H., Pascual-Salcedo, D., de Vries, A., Hart, M., et al. Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. Scand J Rheumatol 46 (2017), 87–94.
34. Lester, S.E., Proudman, S.M., Lee, A.T., Hall, C.A., McWilliams, L., James, M.J., et al. Treatment-induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritis. Intern Med J 39 (2009), 296–303.
35. Gibiansky, L., Frey, N., Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. J Pharmacokinet Pharmacodyn 39 (2012), 5–16.